Crossmark

Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer

Crossref DOI link: https://doi.org/10.1186/s13075-018-1678-9

Published Online: 2018-08-09

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Betteridge, Zoe E.

Priest, Lynsey

Cooper, Robert G.

McHugh, Neil J.

Blackhall, Fiona

Lamb, Janine A. https://orcid.org/0000-0002-7248-0539
License Information

Text and Data Mining valid from 2018-08-09
More Information

Article History

Received: 8 June 2018

Accepted: 17 July 2018

First Online: 9 August 2018

Ethics approval and consent to participate

: Sample collection was undertaken via the Molecular mechanisms underlying chemotherapy resistance, therapeutic escape, efficacy and toxicity - improving knowledge of treatment resistance in patients with lung cancer (ChemoRes) trial .The ChemoRes trial was reviewed in the UK by the National Research Ethics Service Committee North West - Greater Manchester West, which granted ethics approval for the study on 26 February 2008 (REC reference 07/H1014/96).

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.